Association between interleukin-6-174G/C gene polymorphism and asthma severity: exploring the role of total serum IgE, blood eosinophils, and FeNO as markers of type 2 inflammation

Table 2 Characteristics and type 2 biomarkers in asthma patients

Factors	Mild asthma (n = 98)		Severe asthma (n = 116)		p
Smoking	N	%	N	%
Smoker	10	10.2	5	4.31	0.19^c
Ex-smoker	3	3.06	6	5.17
Non-smoker	85	86.73	105	90.52

Asthma onset	N	%	N	%
Adulthood	61	62.24	84	72.41	0.11^c
Childhood	37	37.76	32	27.59

Associated morbidity	N	%	N	%
DM	6	6.12	9	7.76	0.63^c
AR	46	46.94	85	73.28	< 0.001^c
NP	8	8.16	57	49.14	< 0.001^c
Eczema	7	7.14	8	6.9	0.98^c

Evaluation	Mean/median	SD/IQR	Mean/median	SD/IQR
BMI	30.19	6.95	31.46	5.75	0.15^a
IgE	114	(35–298)	275	(130–566)	< 0.001^b
Blood Eosinophil Counts	0.21	(0.1–0.45)	0.41	(0.19–0.73)	0.001^b
FeNO	14.5	(8–25)	23	(11–45)	0.002^b
FEV1% predicted	80.395	(69–111)	58.25	(21–109)	0.03^b

	N	%	N	%
Exacerbation one year before	6	6.12	32	27.59	0.001^c
OCS course number	3	3.06	25	21.5	0.001^c

Numerical data represented as mean and standard deviation or median and inter quartile range, and categorical data as number and percentage
N number, SD standard deviation, IQR Inter quartile range, OR odd ratio, CI Confidence interval, BMI body mass index, IgE immunoglobulin E, FeNO Fractional expired nitric oxide, DM diabetes mellitus, AR allergic rhinitis, NP nasal polyp
^aIndependent t-test
^bMann Whitney test
^cChi square test
Text in Bold represents a significant p value; p < 0.05

ISSN: 1710-1492